News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Tokyo's Nikkei 225 rose 0.94%, driven by gains in real estate, banking and textile stocks.
  • European stocks climbed ahead of the Trump-Xi meeting as oil prices eased.
  • UK equities ticked up following President Trump's arrival in Beijing.
  • President Trump will prioritize artificial intelligence in talks with Xi, but officials do not expect binding deals.
  • Anduril closed a $5 billion funding round, lifting its valuation to $61 billion.
  • Axon reported strong software growth and raised its 2026 revenue guide, supporting investor demand for its SaaS pivot.

Latest Articles

Pound Strengthens as Dollar Sheds Value on Signs of Iran-U.S. Deal; Oil Slides

Pound Strengthens as Dollar Sheds Value on Signs of Iran-U.S. Deal; Oil Slides

Sterling and the euro climbed on Wednesday after reports suggested progress toward an agreement between Washington and Tehran and Iran signalled the Strait of Hormuz could allow safe passage. The moves reflected broad dollar weakness, driven by diplomatic developments that also pressured oil prices. Attention now shifts to U.S. inventory data and d…

BofA Clients Drive Record Weekly ETF Inflows as Stocks Tick Higher

BofA Clients Drive Record Weekly ETF Inflows as Stocks Tick Higher

Bank of America reports that its clients were sizable net purchasers of U.S. equities last week, producing a record $6.8 billion in equity ETF inflows — the largest weekly total since the firm began tracking flows in 2017. Single-stock inflows of $1.9 billion were recorded, the first such buying since early March, as the S&P 500 rose 0.9% and reach…

DeepSeek May Seek Up to $50 Billion Valuation in First Funding Push

DeepSeek May Seek Up to $50 Billion Valuation in First Funding Push

DeepSeek, a Chinese large language model developer, is reportedly preparing its first external fundraising round that could value the company as high as $50 billion. Discussions are said to include China’s 60-billion-yuan national artificial intelligence fund and private technology investors, with the start-up possibly aiming to raise $3 billion to…

SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041

SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041

Scienture Holdings announced that the USPTO has granted a third patent for ARBLI™ (losartan potassium) oral suspension, the first FDA-approved ready-to-use liquid losartan formulation. This patent extends market exclusivity through 2041, strengthening ARBLI™'s position in the $241 million U.S. losartan market with 72 million prescriptions annually.…

StepStone Group and PitchBook Announce Partnership to Deliver Deal-Level Performance & Operating Metrics to Private Market Participants

StepStone Group and PitchBook Announce Partnership to Deliver Deal-Level Performance & Operating Metrics to Private Market Participants

StepStone Group and PitchBook, a Morningstar company, have entered into a partnership to integrate StepStone's proprietary deal-level benchmarks into the PitchBook platform. This collaboration aims to provide private market participants—including fund managers and investors—with advanced, granular analytics and benchmarking tools that improve trans…

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

Orchestra BioMed has received a $15 million payment from Ligand Pharmaceuticals under a royalty-based financing agreement, fulfilling a scheduled tranche and bringing Ligand's total investment to $40 million. This funding, alongside a $20 million investment from Medtronic, supports ongoing pivotal clinical trials for Orchestra's AVIM Therapy and Vi…